Radiotherapy as an effective treatment modality for XXXX : a single institution experience.

@entity1 @entity137 @entity706 @entity75 @entity5 @entity1893 @entity204
PURPOSE: @entity706 ( @entity706 ) is an indolent @entity1893 that is highly sensitive to radiotherapy (RT). However, the effectiveness of RT has not been well established. We reviewed our experiences to assess the role of RT for @entity706 and analyze treatment results. MATERIALS AND METHODS: Retrospective analysis was done on 29 @entity1 who received first RT between January 2003 and August 2013. Of 23 early stage (stage I, II) @entity1 , 16 received RT alone, four received chemotherapy followed by RT, two received RT postoperatively, and one received salvage RT for relapse after resection. Six advanced-stage (stage III, IV) @entity1 received RT after chemotherapy: two received consolidation RT, three received salvage RT for @entity75 , and one received RT for progressive sites. Median RT dose was 30.6 Gy (range, 21.6 to 48.6 Gy). Median follow-up duration was 62 months (range, 6 to 141 months). RESULTS: All @entity1 showed complete response in the radiation field. Eight outfield relapses were reported. Seven @entity1 received salvage treatment (three chemotherapy, four RT). Four @entity1 showed excellent responses, especially to RT. Estimated 5-year and 10-year relapse-free survivals were 72% and 60%. In the RT-alone group, 5-year relapse-free survival was 74.5%. All advanced-stage @entity1 were disease-free with 100% 5-year overall survival. @entity204 was noted in only one @entity1 ; four others died of other unrelated causes. No significant @entity137 was reported. CONCLUSION: RT resulted in excellent treatment outcomes for all @entity706 stages when used as a primary treatment modality for early stage or salvage-treatment modality for @entity5 .
